Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ErbB3

ErbB3

Brief Information

Name:Receptor tyrosine-protein kinase erbB-3
Target Synonym:EC:2.7.10.1,FERLK,EC 2.7.10,Proto-oncogene-like protein c-ErbB-3,HER3,ERBB3,Erb-B2 Receptor Tyrosine Kinase 3,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3,Tyrosine Kinase-Type Cell Surface Receptor HER3,Human Epidermal Growth Factor Receptor 3,Lethal Congenital Contracture Syndrome 2,Receptor Tyrosine-Protein Kinase ErbB-3,EC 2.7.10.1,P180-ErbB3,P45-SErbB3,P85-SErbB3,MDA-BF-1,C-ErbB-3,C-ErbB3,ErbB3-S,ErbB-3,LCCS2,Receptor, ErbB-3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:25
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATP149-Cell-based assay
 ErbB3 FACS

Expression analysis of human ErbB3 on HEK293/Human ErbB3 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human ErbB3 Stable Cell Line or negative control cell using PE-labeled anti-human ErbB3 antibody.

ER3-H82E6-ELISA
 ErbB3 ELISA

Immobilized Biotinylated Human ErbB3, His,Avitag (Cat. No. ER3-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NRG1 Beta 1, Fc Tag, premium grade (Cat. No. NR1-H5268) with a linear range of 0.2-3 ng/mL (QC tested).

ER3-M52H5-MALS-HPLC
ErbB3 MALS images

The purity of Mouse ErbB3, His Tag (Cat. No. ER3-M52H5) is more than 85% and the molecular weight of this protein is around 75-110 kDa verified by SEC-MALS.

Synonym Name

ERBB3,HER3,LCCS2,MDA-BF-1,MGC88033,c-erbB3,erbB3-S,p180-ErbB3,p45-sErbB3,p85-sErbB3

Background

ErbB3,also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation. However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Osimertinib Mesylate AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 Approved Astrazeneca Pharmaceutical Co Ltd 泰瑞沙, Tagrisso Mainland China Carcinoma, Non-Small-Cell Lung Astrazeneca Ab 2015-11-13 Uterine Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Brain metastases; Esophageal adenocarcinoma; Cholangiocarcinoma; Lymphoma; Glioma; Endometrial Neoplasms; Thyroid Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma of Lung; Liver Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Skin Neoplasms; Colonic Neoplasms; Glioblastoma; Multiple Myeloma; Urinary Bladder Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Recombinat humanized HER3-targeting antibody Phase 1 Clinical Shanghai Institute Of Biological Products Co Ltd Solid tumours Details
Sirotinib Maleate XZP-5491 Phase 1 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
GSK-2849330 GSK-2849330 Glaxosmithkline Plc Details
JK-07 JK-07 Shenzhen Salubris Pharmaceuticals Co Ltd Details
Patritumab AMG-888; U3-1287 Amgen Inc, Daiichi Sankyo Co Ltd Details
AV-203 AV-203; CAN-017 Phase 1 Clinical Aveo Neoplasms Details
MP-0274 DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 Molecular Partners Ag Details
Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein(Salubris) SAL-007 Phase 1 Clinical Shenzhen Salubris Pharmaceuticals Co Ltd Heart Failure Details
Recombinant human ErbB3 fragment vaccine (Zensun) rhErbB3-f Phase 1 Clinical Zensun (Shanghai) Sci&Tech Co Ltd Neoplasms Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase 2 Clinical Shanghai Allist Pharmaceutical Technology Co Ltd Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Elgemtumab NOV-6; LJM-716 Phase 1 Clinical Novartis Pharma Ag, Morphosys Ag Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma Details
SIBP-03 SIBP-03 Phase 1 Clinical Shanghai Institute Of Biological Products Co Ltd Neoplasms Details
Barecetamab ISU-104 Phase 1 Clinical Isu Abxis Co Ltd Solid tumours Details
HMBD-001 HMBD-001 Phase 2 Clinical Hummingbird Bioscience Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
KTN-3379 CDX-3379; KTN-3379 Phase 2 Clinical Medimmune Squamous Cell Carcinoma of Head and Neck; Neoplasms; Breast Neoplasms; Thyroid Neoplasms Details
Sapitinib AZD-8931 Phase 2 Clinical Astrazeneca Pharmaceutical Co Ltd Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Tesevatinib XL-647; KD-020; KD-019; EXEL-7647 Phase 2 Clinical Exelixis Inc Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
BL-B01D1 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Neoplasms, Fibroepithelial; Solid tumours; Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Urologic Neoplasms; Gastrointestinal Neoplasms Details
Seribantumab MM-121; SAR-256212; 1N3L70MDFX (UNII code) Phase 2 Clinical Merrimack Pharmaceuticals Inc Sarcoma; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Uterine Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Urinary Bladder Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Head and Neck Neoplasms; Solid tumours Details
Patritumab Deruxtecan U3-1402 Phase 3 Clinical Daiichi Sankyo Co Ltd Breast Neoplasms; Colorectal Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung Details
Zenocutuzumab MCLA-128 Phase 2 Clinical Merus Nv Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Izalontamab SI-B001; SI-1X6.4 Phase 3 Clinical Sichuan Baili Pharmaceutical Co Ltd Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message